Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-hispanic whites

American Journal of Gastroenterology

Volumn 104, Issue 7, 2009, Pages 1686-1692

  Yu, Stanley ^a,b   Douglass, Jeffrey M ^a,b   Qualls, Clifford ^c   Arora, Sanjeev ^a   Dunkelberg, Jeffrey C ^a,d  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b VA Medical Center   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CAUCASIAN; EARLY VIROLOGIC RESPONSE; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE;

ADULT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HISPANIC AMERICANS; HUMANS; INTERFERON ALFA-2A; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW MEXICO; POLYETHYLENE GLYCOLS; PROBABILITY; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67650453450     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.173     Document Type: Article

References (23)

1. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003;7:261-87.
2. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-4.
3. Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
4. Alter MJ, Kruszon-Moran D, Nainan O et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
5. Rodriguez-Torres M. Latinos and chronic hepatitis C: a singular population. Clin Gastroenterol Hepatol 2008;6:484-90.
6. U.S. Census Bureau Population Estimates Available at: http://www.census.gov/popest/estimates.php.
7. U.S. Census Bureau. U.S. Interim Projections by Age, Sex, Race, and Hispanic Origin: 2000-2050, Available at: http://www.census.gov/ipc/www/ usinterimproj/.
8. Brau N, Bini EJ, Currie S et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 2006;13:242-9.
9. Muir AJ, Bornstein JD, Killenberg PG et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
10. Shiffman ML, Mihas AA, Millwala F et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007;102:761-6.
11. Missiha S, Heathcote J, Arenovich T et al. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007;102:2181-8.
12. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999;30:787-93.
13. Gaglio PJ, Rodriguez-Torres M, Herring R et al. Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol 2004;38:599-604.
14. Hepburn MJ, Hepburn LM, Cantu NS et al. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163-8.
15. Cheung RC, Currie S, Shen H et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005;100:2186-93.
16. Rodriguez-Torres M, Jeffers LJ, Sheikh MY et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009;360:257-67.
17. Verma S, Bonacini M, Govindarajan S et al. More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006;101:1817-23.
18. Harrison SA, Brunt EM, Qazi RA et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005;3:604-9.
19. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
20. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 ;33:1358-64.
21. Liakina V, Speiciene D, Irnius A et al. Association of the prevalence and grade of steatosis in patients with chronic hepatitis C with the host and viral factors. Acta Gastroenterol Belg 2007;70: 260-6.
22. Rodriguez-Torres M, Rios-Bedoya CF, Ortiz-Lasanta G et al. Weight affect relapse rates in Latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys)180 meg/week and 800mg daily of ribavirin for 24 weeks. J Medical Virol 2008;80: 1576-80.
23. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123: 1061-9.